III-01 Kristin Dickschen PBPK modeling to guide experimental design in preclinical and clinical development Thursday 10:20-11:45 |
III-02 Irene-Ariadne Kechagia A simulation study to investigate the identifiability of parameters in a minimal PBPK model structure with target binding Thursday 10:20-11:45 |
III-03 Thomas Dorlo Population pharmacokinetics and pharmacodynamics of miltefosine in mono- and combination therapy regimens for visceral leishmaniasis in East Africa Thursday 10:20-11:45 |
III-04 Anne-Gaelle Dosne Determination of Appropriate Settings in the Assessment of Parameter Uncertainty Distributions using Sampling Importance Resampling (SIR) Thursday 10:20-11:45 |
III-05 Stephen Duffull An approximation to the solution of systems of nonlinear ordinary differential equations in pharmacokinetics-pharmacodynamics Thursday 10:20-11:45 |
III-06 Sulav Duwal Systematic in silico analysis of the efficacy of NRTIs for pre-exposure prophylaxis (PrEP) against HIV-1 Thursday 10:20-11:45 |
III-07 Helena Edlund Covariate analysis of infliximab in Crohn’s disease using available PK models as prior Thursday 10:20-11:45 |
III-08 Miro Eigenmann Modeling of acquired resistance under TKI treatment Thursday 10:20-11:45 |
III-09 Rena Eudy-Byrne Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis Thursday 10:20-11:45 |
III-11 Gregory Ferl Mechanistic model of amyloid beta and anti-amyloid beta mAb dynamics Thursday 10:20-11:45 |
III-12 Sylvain Fouliard Interpretability is coming: using a minimal PBPK model in a population analysis Thursday 10:20-11:45 |
III-13 Linda Franken Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill patients. Thursday 10:20-11:45 |
III-15 Achim Fritsch PK/PD Modeling of Sunitinib in Patients with Metastatic Colorectal and Renal Cell Cancer Thursday 10:20-11:45 |
III-16 Aline Fuchs Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants Thursday 10:20-11:45 |
III-17 Saskia Fuhrmann Effect of mouse model immunity on antibody biodistribution Thursday 10:20-11:45 |
III-18 María García-Cremades Modelling tumour growth and survival of patients with pancreatic cancer receiving Gemcitabine Thursday 10:20-11:45 |
III-19 Charkoftaki Georgia Population pharmacokinetics of cyclophosphamide and its 4-OH metabolite in patients with glomerulonephritis Thursday 10:20-11:45 |
III-20 Eva Germovsek An Argument for Standardised Scaling: Comparison of Methods for Scaling Clearance in Children Thursday 10:20-11:45 |
III-21 Leonid Gibiansky Approximations of Target-Mediated Drug Disposition (TMDD) Equations for Systems with 1:2 and 2:1 Drug-Target Binding Stoichiometry Thursday 10:20-11:45 |
III-22 Ekaterina Gibiansky Comparison of Population Pharmacokinetics and Exposure-Response Relationships of Intravenous Rituximab and Subcutaneous Rituxumab in Patients with Chronic Lymphocytic Leukemia Thursday 10:20-11:45 |
III-23 Bojana Golubovic Population pharmacokinetic analysis of tacrolimus TDM data in stable kidney transplant patients Thursday 10:20-11:45 |
III-24 Ignacio Gonzalez-Garcia Development of a Systems Pharmacology Model for Inflammatory Bowel Disease (IBD) Thursday 10:20-11:45 |
III-25 Mario Gonzalez Sales inVentR: a new flexible, powerful and efficient R package for model drug development using NONMEM®. Thursday 10:20-11:45 |
III-26 Isabel Gonzalez-Alvarez Modelling of intestinal degradation and absorption of Clavulanic acid from In Vitro and In Situ data. Thursday 10:20-11:45 |
III-27 Verena Gotta A PK/PD meta-analysis to assess inter-study variability and translational value of preclinical exposure-QTc predictions Thursday 10:20-11:45 |
III-28 Thaddeus Grasela Toward Progressive Reporting of Modeling and Simulation Results – Part 1: Analysis of KIWI™ Metadata Thursday 10:20-11:45 |
III-29 Bruce Green Impact of Concomitant Antiretrovirals, and CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine Thursday 10:20-11:45 |
III-30 Jinju Guk Model-based assessment of risks and benefits of tissue plasminogen activator treatment in acute ischemic stroke Thursday 10:20-11:45 |
III-31 Beatriz Guglieri-Lopez A tumour growth inhibition model based on serum M-protein levels in patients with multiple myeloma treated by lenalidomide. Thursday 10:20-11:45 |
III-32 Benjamin Guiastrennec In vitro-in vivo modeling of erosion profiles for HPMC/DCP gel matrix tablets Thursday 10:20-11:45 |
III-33 Gustaf Wellhagen Quantifying drug effects in phase 2a anti-diabetic studies: Power and accuracy of four HbA1c models Thursday 10:20-11:45 |
III-34 K. Melissa Hallow Interactive evaluation of dosing regimens for a novel anti-diabetic agent: a case-study in the application of RxODE Thursday 10:20-11:45 |
III-35 Kelong Han Tumor Growth Inhibition Modeling of Onartuzumab in Combination with Erlotinib Does Not Suggest Dose Intensification Would Improve Outcome in Patients with 2nd and 3rd Line Non-small Cell Lung Cancer Thursday 10:20-11:45 |
III-36 Jacqueline Hannam A model for the respiratory effects of remifentanil and propofol during sedation and analgesia Thursday 10:20-11:45 |
III-37 Michael Heathman A Joint Concentration-Response Model for ABPM Measurements of Systolic and Diastolic Blood Pressure Thursday 10:20-11:45 |
III-38 Andrea Henrich External evaluation of a PK/PD model describing the time course of paclitaxel and neutropenia in patients with advanced non-small cell lung cancer Thursday 10:20-11:45 |
III-39 Young-A Heo Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine Thursday 10:20-11:45 |
III-40 Christoph Hethey Mechanism-based pharmacodynamic modelling of bacterial growth inhibition by antibiotics Thursday 10:20-11:45 |
III-41 Jules Heuberger Population Pharmacokinetic/Pharmacodynamic Modeling of a next generation recombinant human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3. Thursday 10:20-11:45 |
III-42 Rollo Hoare Modelling CD4 T cell reconstitution in HIV-infected children starting antiretroviral therapy Thursday 10:20-11:45 |
III-43 Richard Höglund Artemether-lumefantrine coadministration with antiretrovirals; population pharmacokinetics and dosing implications Thursday 10:20-11:45 |
III-44 Nick Holford The Influence of Body Composition on Ethanol Pharmacokinetics using a Rate Dependent Extraction Model Thursday 10:20-11:45 |
III-45 Xiao Hu Exposure-Response Analysis of Peginterferon Beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Thursday 10:20-11:45 |
III-46 Moustafa M. A. Ibrahim Design of Phase I Studies based on Mechanism of Action of Anti-Diabetic Drugs; Assessing power, precision and accuracy in a simulation study of glucose tolerance tests Thursday 10:20-11:45 |
III-47 Itziar Irurzun-Arana Methodology for Boolean Modeling of Biological Networks Applied to Systems Pharmacology Thursday 10:20-11:45 |
III-48 Esther Janssen Population pharmacokinetic analysis of lamivudine in children aged 5 months – 18 years Thursday 10:20-11:45 |
III-49 Nerea Jauregizar Pharmacokinetic/Pharmacodynamic modeling of dynamic time-kill curves for anidulafungin against Candida Thursday 10:20-11:45 |
III-50 Shuangmin Ji Model-based Meta-analysis to Determine the Efficacy of Entecavir and Adefovir in the Treatment of Chronic Hepatitis B Thursday 10:20-11:45 |
III-51 Feng Jin Population Pharmacokinetic Modeling of Sofosbuvir, a NS5B Polymerase Inhibitor, and Its Metabolites, in Patients with Hepatitis C Virus Infection Thursday 10:20-11:45 |
III-53 Mats Jirstrand Sensitivity Equations Provide More Robust Gradients and Faster Computation of the FOCE Approximation to the Population Likelihood Thursday 10:20-11:45 |
III-54 Åsa Kragh Application of an Item Response Theory model to describe Amyotrophic Lateral Sclerosis Functional Rating Scale data Thursday 10:20-11:45 |
III-55 Francine Johansson Azeredo Comparing the fungicidal effect of free amphotericin B with to a novel miccele system against Candida albicans by a PK/PD modeling approach Thursday 10:20-11:45 |
III-56 Niclas Jonsson Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations Thursday 10:20-11:45 |
III-57 Amita Joshi Survey of methodologies for exposure-response analysis of oncology drugs approved in FDA from 2010 to 2013 Thursday 10:20-11:45 |
III-58 Marija Jovanovic Nonlinear mixed effects modelling approach in investigating amitriptyline pharmacokinetics Thursday 10:20-11:45 |
III-59 Vincent Jullien Population pharmacokinetics of bumetanide in term newborn infants with seizures Thursday 10:20-11:45 |
III-60 Rasmus Juul Kildemoes Exploring the relationship between analgesic event rate and pain intensity in kidney stone surgery: A Repeated Time to Event Pilot Study Thursday 10:20-11:45 |
III-61 Matts Kågedal Binning of exposures in survival analysis for oncology – A simulation study Thursday 10:20-11:45 |
III-62 Vangelis Karalis A computational methodology for the validation of the terminal slope estimate Thursday 10:20-11:45 |
III-63 Mats Karlsson Influence of clinical trial design to detect drug effect in systems with within subject variability Thursday 10:20-11:45 |
III-64 Evgenia Kartsaki Translating Pharmacogenomics for Personalised Medicine Thursday 10:20-11:45 |
III-65 Ron Keizer New open source R libraries for simulation and visualization: “PKPDsim” and “vpc” Thursday 10:20-11:45 |
III-66 Lena Klopp-Schulze In silico simulation study: A comparison of two population pharmacokinetic models of tamoxifen and its major metabolite endoxifen Thursday 10:20-11:45 |
III-67 Jane Knöchel Impact of randomness of mutation dynamics on the development of drug resistance under antiviral therapy Thursday 10:20-11:45 |
III-68 Gilbert Koch Model for characterizing copeptin kinetics and response in healthy volunteers Thursday 10:20-11:45 |
III-69 Stephan Koehne-Voss The impact of unmodelled interoccasion variability in bioavailability and absorption on parameter estimates in population pharmacokinetic analysis Thursday 10:20-11:45 |
III-70 Julia Korell A population pharmacokinetic model for aripiprazole and dehydro-aripiprazole Thursday 10:20-11:45 |
III-71 Wojciech Krzyzanski Physiologically structured population model (PSP) of heterogeneity of target binding to describe resistance of Gram-negative bacteria to polymyxin B (PB) Thursday 10:20-11:45 |
III-72 Anne Kuemmel Calculation of confidence and prediction intervals for pharmacokinetic and pharmacodynamic models Thursday 10:20-11:45 |
III-73 Brigitte Lacroix A time-to-event model for the immunogenicity of certolizumab pegol in rheumatoid arthritis subjects Thursday 10:20-11:45 |
III-74 Silvia Maria Lavezzi Toxicity assessment via drug-drug interaction modeling for trabectedin in patients with advanced malignancies Thursday 10:20-11:45 |
III-75 Olivia le Saux Development and validation of a model of PSA kinetics predicting prostate cancer aggressiveness during screening Thursday 10:20-11:45 |
III-76 SeungHwan Lee A population pharmacokinetic analysis of CKD-516 in patients with advanced solid tumor Thursday 10:20-11:45 |
III-77 Donghwan Lee Population pharmacokinetic analysis of Doripenem in Korean patients with acute infections Thursday 10:20-11:45 |